Methods for quantitating IL-33

The method addresses interference issues in IL-33 immunoassays by acidifying and neutralizing samples with a buffered solution, using streptavidin-coated plates and labeled antibodies, achieving high sensitivity and tolerance for ST2 interference, thus ensuring accurate IL-33 quantification.

JP7586984B2Active Publication Date: 2024-11-19REGENERON PHARMACEUTICALS INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023126792
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-04-11
Filing Date
2023-08-03
Publication Date
2024-11-19
Estimated Expiration
2039-04-10

AI Technical Summary

Technical Problem

Existing immunoassays for detecting and quantifying IL-33 suffer from unreliable results due to interference from endogenous binding partners such as the soluble ST2 receptor, leading to misinterpretation of patient results and incorrect treatment courses.

Method used

A method involving acidification of the sample to dissociate IL-33 complexes, followed by neutralization with a buffered basic solution containing a detection reagent and optionally a blocking agent to inhibit complex reformation, using streptavidin-coated plates with biotinylated anti-human IL-33 antibodies and ruthenium-labeled antibodies for quantification.

Benefits of technology

The method reduces assay interference, achieving a sensitivity of 12.5 pg/mL and an ST2 tolerance of greater than 50 ng/mL, providing accurate and reliable quantification of IL-33 levels.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007586984000002
    Figure 0007586984000002
  • Figure 0007586984000003
    Figure 0007586984000003
  • Figure 0007586984000004
    Figure 0007586984000004
Patent Text Reader

Abstract

To provide methods and compositions for detecting and quantifying cytokines.SOLUTION: The disclosed assays have reduced assay interference compared to commercially available assays and / or a control assay. The interference can be cytokine-dependent, cytokine-independent, or both. One embodiment provides an IL-33 immunoassay that reduces assay interference caused by endogenous soluble IL-33 binding molecules present in a sample. Exemplary soluble IL-33 binding molecules include, but are not limited to anti-IL-33 antibodies, soluble ST2 receptor, and serum components. In some embodiments, a blocking agent is added to the sample to reduce, inhibit or block reformation of IL-33 complexes in the sample after acid dissociation of the IL-33 complexes in the sample. In one embodiment, the blocking agent and the detection reagent do not compete for binding to IL-33.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 655,887, filed April 11, 2018, which is incorporated by reference in its entirety.

[0002] TECHNICAL FIELD OF THEINVENTION Aspects of the present invention relate generally to immunoassays for the detection and quantification of cytokines, including, but not limited to, interleukin-33 (IL-33). [Background technology]

[0003] 2. Background of the Invention Interleukin 33 (IL-33) is a cytokine that increases in response to injury signals or insults, such as cigarette smoke. The cytokine is released by barrier tissues during necrosis and propagates an immune response to the presence of damaged tissue. This "alarmin" signal amplifies inflammatory responses to both innate and adaptive immunity. Published data indicate that commercially available kits for detecting soluble IL-33 generate unreliable results, likely due to interference from endogenous binding partners such as the soluble ST2 receptor (Nygaard, U., et al., SpringerPlus, 5:33 (2016) (Non-Patent Document 1); Ketelaar, ME, Clin Exp Allergy, 46 (6): 884-7 (2016) (Non-Patent Document 2); Riviere, E. et al., Ann Rheum Dis, 75 (3): 633-5 (2016) (Non-Patent Document 3)).

[0004] The performance of ligand binding assays in complex matrices such as serum can be affected by certain endogenous components that interfere with the assay (Zhong, ZD, et al., AAPS J, 19:1564 (2017) (Non-Patent Document 4)). Interference in immunoassays can lead to misinterpretation of patient results by laboratories and incorrect courses of treatment given by physicians (Tate, J., et al. Clin Biochem Rev. 2004, 25(2):105-120 (Non-Patent Document 5)).

[0005] Attempts to develop better immunoassays have been made by others. Doucet, J. et al. reported an improved IL-13 assay that includes an acid dissociation step (Doucet, J. et al., Disease Markers, 35(5):465-474 (2013) (Non-Patent Document 6)). The immunoassay described by Doucet is specific for IL-13 but did not detect IL-33. In addition, Doucet's immunoassay did not require neutralization of the sample prior to detection and did not use a blocking agent to prevent reformation of cytokine complexes during the assay.

[0006] Therefore, there is a need for new assays and methods for the detection of IL-33. [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Nygaard, U.,et al.,SpringerPlus,5:33(2016) [Non-Patent Document 2] Ketelaar, ME, Clin Exp Allergy, 46(6):884~7(2016) [Non-Patent Document 3] Riviere, E. et al., Ann Rheum Dis,75(3):633-5(2016) [Non-Patent Document 4] Zhong,ZD,et al.,AAPS J,19:1564(2017) [Non-Patent Document 5] Tate, J., et al.Clin Biochem Rev.2004,25(2):105~120 [Non-Patent Document 6] Doucet, J. et al., Disease Markers, 35(5):465~474(2013) Summary of the Invention

[0008] Methods and compositions are provided for detecting and quantifying cytokines. The disclosed assays have reduced assay interference compared to commercially available assays and / or control assays. The interference can be cytokine-dependent, cytokine-independent, or both. One embodiment provides an IL-33 immunoassay that reduces assay interference caused by endogenous soluble IL-33 binding molecules present in the sample. Exemplary soluble IL-33 binding molecules include, but are not limited to, anti-IL-33 antibodies, soluble ST2 receptors, and serum components. In some embodiments, a blocking agent is added to the sample to reduce, inhibit, or block the reformation of IL-33 complexes in the sample after acid dissociation of the IL-33 complexes in the sample. In one embodiment, the blocking agent and the detection reagent do not compete for binding to IL-33.

[0009] Another embodiment provides a method for determining the concentration of total IL-33 in a human serum sample using an electrochemiluminescence immunoassay. The assay involves acid pretreatment of the serum sample to dissociate soluble ligand:drug complexes present in the sample and improve detection of IL-33 in the presence of drug, thus providing a quantitative measurement of the level of total IL-33. In this embodiment, the procedure uses streptavidin-coated plates with biotinylated anti-human IL-33 antibodies as capture reagents and utilizes recombinant IL-33 as a standard. Standards, controls, and samples are diluted with acetic acid and neutralized using a Tris base solution containing a detection reagent, e.g., a ruthenium-labeled anti-human IL-33 antibody. Antibodies that bind to the anti-IL-33 antibody and anti-ST2 receptor antibody are also added to the Tris solution to minimize interference from the drug (i.e., antibodies that bind the antibody to IL-33) or endogenous soluble ST2 receptor. The neutralized standards, controls, and samples are then added to the plate. The IL-33 captured on the plate is measured in a plate reader by the chemiluminescent signal generated by the ruthenium label when a voltage is applied to the plate. The resulting electrochemiluminescent signal (i.e., counts) is proportional to the amount of IL-33 present in the serum sample.

[0010] In one embodiment, the method has a sensitivity of 12.5 pg / mL and an ST2 tolerance of greater than 50 ng / mL. [The present invention 1001] 1. A method for reducing assay interference, comprising: acidifying the sample to a pH sufficient to dissociate IL-33 from IL-33 complexes in said sample; followed by neutralizing the acidified sample with a buffered basic solution containing a detection reagent and, optionally, a blocking agent that inhibits IL-33 complex formation; adding a capture reagent to the sample; detecting the detection agent; wherein the amount of the detection reagent detected correlates with the amount of the IL-33 in the sample. [The present invention 1002] The method of claim 10, wherein the sample comprises blood, serum, or plasma. [The present invention 1003] The method of claim 1002, wherein said sample is derived from a subject administered an IL-33 formulation. [The present invention 1004] The method of claim 1003, wherein said IL-33 preparation comprises an anti-IL-33 antibody. [The present invention 1005] The method of any of claims 1001 to 1004, wherein the IL-33 complex comprises IL-33 non-covalently bound to a protein. [The present invention 1006] The method of any one of claims 1 to 5, wherein the protein is an endogenous serum protein. [The present invention 1007] The method of claim 10, wherein said protein is ST2 or an IL-33 binding fragment thereof. [The present invention 1008] The method of claim 10, wherein said protein is an anti-IL-33 antibody or an IL-33 binding fragment thereof. [The present invention 1009] The method of any of claims 1001 to 1008, wherein the sample is acidified to a pH of from 3 to 5. [The present invention 1010] The method of any one of claims 1001 to 1009, wherein the sample is acidified for 5 to 60 minutes. [The present invention 1011] The method of any of claims 1001 to 1010, wherein the detection reagent comprises an anti-IL-33 antibody conjugated to a detectable label. [The present invention 1012] The method of any of claims 1001 to 1011, wherein the detection reagent comprises a detectable agent selected from the group consisting of rare transition metal particles, fluorophores, chromophores, quantum dots, and precious metal nanoparticles. [The present invention 1013] The method of any one of claims 1001 to 1012, wherein the detection reagent is labeled with ruthenium. [The present invention 1014] The method of any of claims 1001 to 1013, wherein said capture reagent is conjugated to a solid support. [The present invention 1015] The method according to any one of claims 1001 to 1014, wherein said capture reagent is biotinylated. [The present invention 1016] The method of any one of claims 1001 to 1015, wherein the sample is acidified with acetic acid. [The present invention 1017] The method of any one of claims 1001 to 1016, wherein said blocking agent is an antibody. [The present invention 1018] The method of any of claims 1001 to 1017, wherein said blocking agent is an anti-ST2 antibody. [The present invention 1019] The method of any one of claims 1001 to 1018, wherein said capture reagent is added to said sample during said acidification step. [The present invention 1020] The method of any one of claims 1001 to 1019, wherein said detection agent is added to said sample after said neutralization step. [The present invention 1021] The method of any one of claims 1001 to 1020, wherein said capture reagent and said detection reagent are added to said sample after said neutralization step. [The present invention 1022] Any of the methods of claims 1001 to 1021, having a sensitivity of 12.5 pg / mL. [The present invention 1023] Any of the methods of claims 1001 to 1022, having ST2 tolerance of more than 50 ng / mL. [The present invention 1024] The method of any of claims 1001 to 1023, wherein said sample is obtained from a subject diagnosed with or suspected of having an inflammatory disease or disorder. [The present invention 1025] The method of any one of claims 1001 to 1024, wherein the sample is obtained from a subject diagnosed with or suspected of having asthma, chronic obstructive pulmonary disease, or atopic dermatitis. [The present invention 1026] The method of any one of claims 1014 to 1025, wherein the solid support is an electrochemiluminescence platform. [The present invention 1027] The method of any of claims 1001 to 1026, wherein said amount of IL-33 is determined by correlating the amount of the detection reagent detected with a predetermined reference standard. [The present invention 1028] 1. A method for quantifying interleukin-33 in a serum sample, comprising: acidifying the serum sample to a pH sufficient to dissociate IL-33 complexes in the sample; Neutralizing the acidified sample with a buffered basic solution comprising (a) an anti-human IL-33 antibody labeled with a detectable label, and optionally (b) an anti-human ST2 antibody; adding the sample to an avidin-coated solid support containing a biotinylated anti-human IL-33 antibody; detecting the detectable label on the avidin-coated solid support; wherein the amount of detectable label detected correlates with the amount of IL-33 in the sample. [The present invention 1029] The method of claim 1028, wherein said solid support is a streptavidin-coated electrochemiluminescence platform. [The present invention 1030] 1029. The method of any of claims 1028 or 1029, wherein said detectable label is ruthenium. [The present invention 1031] The method of any of claims 1028 to 1030, wherein said anti-human ST2 antibody is present in an amount sufficient to reduce binding of ST2 to IL-33 in said sample. [The present invention 1032] Any of the methods of claims 1028 to 1030, having a sensitivity of 12.5 pg / mL and an ST2 tolerance of more than 50 ng / mL. [Brief description of the drawings]

[0011] FIG. 1 is a diagram of an exemplary assay scheme according to an embodiment of the present invention. TIFF0007586984000001.tif6128 (Figure 2A) A line graph of the recovery rate versus the concentration of rhST2 (ng / mL). (■) C-AD with acid treatment; (●) C-AD without acid; (□) CAD with acid treatment; (○) CAD without acid. (FIG. 2B) Bar graph showing endogenous IL-33 detection in serum from three individuals (individual 1, individual 2, and individual 3) assayed under the conditions indicated: no CAD acid, no C-AD acid, CAD acid, and C-AD acid. (FIG. 3) Bar graph showing endogenous IL-33 specificity in serum from individual 1 and individual 3 using the modified assay, addition of rST2, and addition of anti-IL-33 monoclonal antibody. (Figure 4) A graph of IL-33 concentrations (pg / mL) for individual 1 and individual 3 after multiple measurements demonstrating the accuracy of the assay. (FIG. 5) Line graph showing the permissibility of the method for detecting IL-33 in the presence of anti-IL-33 monoclonal antibodies assayed under the conditions indicated: C-AD with acid treatment, and CAD- with acid treatment. (FIG. 6) Graph of endogenous IL-33 (pg / mL) in serum from normal individuals and individuals with asthma, COPD, and atopic dermatitis. 25 individuals each from four different populations were purchased from a commercial vendor and screened for endogenous IL-33 using the C-AD assay with acid treatment. (FIG. 7A) FIG. 7A and FIG. 7B are graphs showing human IL-33 (pg / mL) from treated and control mice. (Figure 7B) Figures 7A and 7B are graphs showing human IL-33 (pg / mL) from treated and control mice. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] Detailed Description of the Invention I. Definition It is to be understood that the disclosure is not limited to the compositions and methods described herein, as well as the experimental conditions described, since they may vary. Also, since the scope of the disclosure is limited only by the appended claims, it should be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0013] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. However, any compositions, methods, and materials similar or equivalent to those described herein can be used to carry out or test the present invention. All publications mentioned are incorporated herein in their entirety by reference.

[0014] The term "binding molecule", as used herein, is intended to refer to a molecule that specifically interacts with and binds to a particular target. Targets may include biological or small (chemical) molecules. Target molecules may define antigens or antigenic moieties. Examples of binding molecules include, but are not limited to, antibodies (including monoclonal antibodies, bispecific antibodies, and antibody fragments), fusion proteins, and other antigen-binding molecules known to those skilled in the art.

[0015] The term "antibody," as used herein, is an example of a binding molecule and refers to an immunoglobulin that generally comprises four polypeptide chains, two heavy (H) chains, and two light (L) chains, inter-connected by disulfide bonds. Each heavy chain contains a heavy chain variable region (HCVR or V H ) and a heavy chain constant region. The heavy chain constant region is H 1. C H 2, and C H Each light chain contains three domains: the light chain variable region (LCVR or V L ) and a light chain constant region. The light chain constant region comprises one domain (C L 1) is included. H Area and V LThe regions can be further subdivided into regions of hypervariability, called complementarity determining regions (CDRs), interspersed with regions that are more conserved, called framework regions (FRs). H and V L is composed of three CDRs and four FRs, arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0016] As used herein, the term "antigen-binding portion" of an antibody (or simply "antibody portion" or "antibody fragment") refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., hIL-33). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term "antigen-binding portion" of an antibody include (i) Fab fragments, V L , V H , C L 1, and C H (ii) a monovalent fragment containing a F(ab')2 fragment, a bivalent fragment containing two F(ab)' fragments linked by a disulfide bridge at the hinge region; (iii) a V H and C H (iv) an Fc fragment containing one domain of a single arm of an antibody; L and V H (v) a dAb fragment comprising a VH domain (Ward, ES, et al., Nature 241:544-546 (1989)), and (vi) a CDR. L and V H Although the V L and V HThe domains may be linked by a synthetic linker that allows them to be produced as a single continuous chain that pairs to form a monovalent molecule (known as single chain Fv (scFv), see, e.g., Bird, RE, et al., Science 242:423-426 (1988), and Huston, JS, et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988)). Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody. Other forms of single chain antibodies, such as diabodies, are also encompassed (see, e.g., Holliger, P., et al., Proc. Natl. Acad Sci. USA 90:6444-6448 (1993)).

[0017] "CDRs" or complementarity determining regions are hypervariable regions interspersed within more conserved regions called "framework regions" (FRs). The FRs may be identical to human germline sequences or may be naturally or artificially modified.

[0018] The term "epitope" is an antigenic determinant that interacts with a specific antigen-binding site, known as the paratope, in the variable region of an antibody molecule. A single antigen may have more than one epitope. Epitopes can be either conformational or linear. Conformational epitopes are generated by spatially juxtaposed amino acids from different segments of a linear polypeptide chain. Linear epitopes are those generated by adjacent amino acid residues in a polypeptide chain. In certain circumstances, epitopes may include sugar, phosphoryl, or sulfonyl moieties on the antigen.

[0019] The term "assay interference" refers to endogenous components in an assay that block or inhibit the detection of an analyte, such as an IL-33 antibody or an anti-IL-33 antibody. Substances that change the measurable concentration of an analyte or that alter antibody binding can potentially result in immunoassay interference. Assay interference can be analyte-dependent or independent. Analyte-independent interference refers to the general interference of hemolysis, lipemia, and the effects of anticoagulants and sample storage, and is not dependent on the analyte concentration. Analyte-dependent interference in an immunoassay refers to the interaction of components in a sample with one or more reagent antibodies. They include compounds that have chemical differences but structural similarities that cross-react with antibodies. Interfering endogenous substances, be they natural polyreactive antibodies or autoantibodies (heterophiles), human anti-animal antibodies, or anti-drug antibodies (ADA), as well as other unsuspected binding proteins specific to an individual, can interfere with the reaction between the analyte and the reagent antibodies in an immunoassay. The interference may be caused by a soluble binding target of the analyte, an endogenous ligand of the analyte including but not limited to a soluble receptor of the analyte, a soluble ligand of the analyte, a shed receptor of the analyte, or serum factors such as rheumatoid factor and biotin. The interference may be caused by an antibody to the analyte.

[0020] The term "ST2" refers to the receptor for IL-33, also called interleukin-1 receptor-like 1 (IL-1RL1). ST2 can be membrane bound or soluble.

[0021] The term "immunoassay" refers to a detection assay that incorporates a binding moiety that directly or indirectly binds to an analyte in an immunospecific manner. Typically, the binding moiety is an antibody. The antibody can be labeled with a detectable label.

[0022] The term "IL-33 complex" refers to a non-covalent association of IL-33 with a component of blood, plasma, or serum. Generally, an IL-33 complex contains IL-33 non-covalently bound to a protein, such as a protein pharmaceutical, an anti-drug antibody, a ligand for IL-33, or a combination thereof.

[0023] II. IL-33 Detection and Quantitation Assays and Methods of Use Assays and methods are provided for the detection and quantification of IL-33. The disclosed assays and methods can be used to detect and quantify IL-33 in a sample. In one embodiment, the sample is obtained from a subject who has been or is being treated with an IL-33 antagonist or IL-33.

[0024] The disclosed assay has reduced assay interference compared to commercial assays and / or control assays. The interference can be IL-33-dependent, IL-33-independent, or both. In one embodiment, the method reduces or inhibits assay interference caused by endogenous soluble IL-33 binding molecules present in the sample. Exemplary soluble IL-33 binding molecules include, but are not limited to, anti-IL-33 antibodies, soluble ST2, and serum components. In some embodiments, a blocking agent is added to the sample to reduce, inhibit, or block the reformation of IL-33 complexes in the sample after acid denaturation of the IL-33 complexes in the sample. In one embodiment, the blocking agent and the detection reagent do not compete for binding to IL-33.

[0025] In one embodiment, the method has a sensitivity of 12.5 pg / mL and an ST2 tolerance of greater than 50 ng / mL.

[0026] A. Interleukin 33 In one embodiment, IL-33 or "human interleukin-33" or "human IL-33" refers to the 270 amino acid full-length, unprocessed IL-33 (see, e.g., UniProtKB Accession No. O95760 and U.S. Patent Publication No. 20180155436, both of which are incorporated by reference in their entirety), or biologically active fragments thereof, as well as any form of IL-33 that results from processing within a cell. The term also encompasses naturally occurring variants of IL-33, such as splice variants (see, e.g., Hong, et.al., (2011), J. Biol. Chem. 286(22):20078-20086), or allelic variants, or any other isoform of IL-33, such as the oxidized or reduced forms of IL-33 described in WO2016 / 156440. Activities of IL-33 that may be neutralized, inhibited, blocked, abrogated, attenuated, reduced, or interfered with by an antibody or antigen-binding fragment thereof, or by an IL-33 trap, include, but are not limited to, inhibition of IL-33 receptor-mediated signaling, or inhibition of IL-33-mediated inflammation.

[0027] B. Methods for detecting IL-33 One embodiment provides a method for detecting IL-33 in a sample by acidifying the sample to a pH sufficient to dissociate IL-33 complex in the sample and neutralizing the acidified sample with a buffered basic solution.To detect IL-33, a capture agent and a detection agent are also added to the sample.In certain embodiments, a blocking agent is added to the sample to inhibit, reduce or block the binding of components in the sample to IL-33.

[0028] Another embodiment provides a method for reducing assay interference by acidifying a sample to a pH sufficient to dissociate IL-33 from the IL-33 complex in the sample, and then neutralizing the acidified sample with a buffered basic solution containing a detection reagent. Optionally, a blocking agent that inhibits the reformation of IL-33 complex in the sample can be added to the sample in a separate step or can be present in the buffered basic solution. The method includes adding a capture reagent to the sample and detecting a detection agent, and the amount of detection reagent detected correlates with the amount of IL-33 in the sample. The capture agent can be added as a separate step or can be present in the acidification step or in the buffered basic solution. Generally, the IL-33 complex present in the sample contains IL-33 non-covalently bound to soluble ST2.

[0029] Another embodiment provides a method of quantifying interleukin-33 in a serum sample by acidifying the serum sample to a pH sufficient to dissociate IL-33 complexes in the sample, and then neutralizing the acidified sample with a buffered basic solution containing (a) an anti-human IL-33 antibody labeled with a detectable label, and optionally (b) an anti-human ST2 antibody. The method includes adding the sample to a streptavidin-coated solid support containing a biotinylated anti-human IL-33 antibody, and detecting the detectable label on the avidin-coated solid support, where the amount of detectable label detected correlates with the amount of IL-33 in the sample.

[0030] Another embodiment provides a method for determining the concentration of total IL-33 in a human serum sample using an electrochemiluminescence immunoassay. The assay includes an acid pretreatment of the serum sample to dissociate soluble ligand:drug complexes present in the sample and improve the detection of IL-33 in the presence of drug, thus providing a quantitative measurement of the level of total IL-33. Ligand:drug complexes include, but are not limited to, IL-33 non-covalently bound to an anti-IL-33 antibody. Exemplary anti-IL-33 antibodies are disclosed in U.S. Patent Nos. 10,000,564 and 9,453,072, which are incorporated by reference in their entirety. In this embodiment, the procedure uses streptavidin-coated plates with biotinylated anti-human IL-33 antibody as the capture reagent and utilizes recombinant IL-33 as the standard. Standards, controls, and samples are diluted with acetic acid and neutralized using a Tris base solution containing a detection reagent, for example, a ruthenium-labeled anti-human IL-33 antibody. Antibodies that bind to the anti-IL-33 and anti-ST2 receptor antibodies are also added to the Tris solution to minimize interference from drugs or endogenous soluble ST2 receptors. Neutralized standards, controls, and samples are then added to the plate. The IL-33 captured on the plate is measured in a plate reader by the chemiluminescent signal generated by the ruthenium label when a voltage is applied to the plate. The resulting electrochemiluminescent signal (i.e., counts) is proportional to the amount of IL-33 present in the serum sample.

[0031] In one embodiment, the amount of label detected in the sample is compared to a reference standard calibrated with a known concentration of IL-33 and the corresponding amount of detection label for that concentration. The amount of IL-33 in the sample can be determined by comparing the amount of detection label in the sample to the reference label and matching the amount of detection label to the concentration shown for the reference label for that amount of detection label.

[0032] 1. Biological Samples The sample used in the disclosed method is typically a biological sample, such as biological fluid, that contains the analyte to be detected, for example IL-33 or its complex.Biological fluids include, but are not limited to, blood, plasma, serum and saliva.In a preferred embodiment, the biological sample is a human biological sample.

[0033] In certain embodiments, the sample is obtained from a subject having or suspected of having an inflammatory condition, disease, or disorder. Exemplary inflammatory conditions, diseases, and disorders include, but are not limited to, Crohn's disease, colitis, ulcerative colitis, atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis, eosinophilic esophagitis, nasal polyps, or combinations thereof.

[0034] The analyte to be detected is generally a component of the serum collected from a subject, preferably a human subject.Representative analytes to be detected and / or quantified in a sample include, but are not limited to, cytokines, protein preparations, and metabolites or fragments thereof.

[0035] Representative cytokines include interleukins, including IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, and IL-36. In one embodiment, the analyte is IL-33.

[0036] Representative protein preparations include, but are not limited to, recombinant proteins, antibodies, and fusion proteins.Antibodies can be polyreactive or autoantibodies (heterophilic), human anti-animal antibodies, or anti-drug antibodies.In one embodiment, the protein preparation is an anti-IL-33 antibody.

[0037] 2.IL-33 Ligand A ligand for IL-33 is a molecule that binds non-covalently to IL-33 and includes, but is not limited to, endogenous components in a sample such as an antibody or a soluble binding target of the analyte, and endogenous ligands for IL-33 include, but are not limited to, a soluble receptor for IL-33, a soluble ligand for IL-33, and a shed receptor of the analyte. In one embodiment, the ligand for IL-33 is a soluble ST2 receptor or a soluble co-receptor IL-1 receptor accessory protein (IL-1RAcP).

[0038] ST2 (also known as IL1RL1, DER4, T1, and FIT-1) is a member of the Toll-like / IL-1 receptor superfamily. Members of this superfamily are defined by a common intracellular domain, the Toll / Interleukin-1 Receptor (TIR) ​​domain. This domain of approximately 160 amino acids consists of a central five-stranded β-sheet surrounded by five α-helices located at the cytoplasmic end of the protein. The Toll-like / IL-1 receptor superfamily can be divided into three subfamilies based on their extracellular domains: the IL-1 receptor-like subfamily, the Toll receptor subfamily, and the family composed of their adaptor proteins.

[0039] 3. Acid denaturation of IL-33 complex The sample in the disclosed method may be acidified for 1 to 60 minutes. In one embodiment, the sample is acidified for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 minutes.

[0040] Acids that can be used in the acidification step include, but are not limited to, acetic acid, hydrochloric acid, and sulfuric acid.

[0041] The pH sufficient to dissociate the IL-33 complex can be between 3.0 and 5.0, in one embodiment, the pH is 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, or 5.0.

[0042] In one embodiment, a denaturing agent can be added to the sample to dissociate the IL-33 complex, including but not limited to urea.

[0043] 4. Blocking agents The blocking agent used in the disclosed method is an agent that reduces or prevents the reformation of IL-33 complex in the sample after the IL-33 complex is dissociated in the acidification step.When the sample is taken from a subject, for example a human subject, the sample typically contains the IL-33 complex to be detected or quantified.The blocking agent can be an antibody that immunospecifically binds to a component of the IL-33 complex other than IL-33.In one embodiment, the blocking agent is an anti-ST2 antibody.

[0044] In one embodiment, the blocking agent is an antibody that binds to the IL-33 preparation, e.g., an antibody that binds to an anti-IL-33 antibody.

[0045] 5. Detection Reagents The detection reagent used in the disclosed methods can be an IL-33 antagonist or inhibitor, such as an anti-IL-33 antibody, preferably an anti-human IL-33 antibody or an IL-33 trap. The antibody can be a monoclonal, polyclonal, or humanized antibody.

[0046] In some embodiments, the detection reagent is labeled with detectable label.Detectable label is known in the art, and includes but is not limited to rare transition metal particles, fluorophores, chromophores, quantum dots, noble metal nanoparticles, radioactive moieties, enzymes, biotin / avidin labels, and chemiluminescent labels.In one embodiment, the detectable label is ruthenium.

[0047] Anti-IL-33 antagonist In certain embodiments, IL-33 antagonists or inhibitors that can be used in the disclosed assays and methods are anti-IL-33 antibodies or antigen-binding fragments of antibodies that specifically bind to human IL-33. In one embodiment, the anti-IL-33 antibodies described herein for use in the disclosed methods and assays are disclosed in U.S. Patent Nos. 10,000,564 and 9,453,072, which are incorporated by reference in their entireties.

[0048] The anti-IL-33 antibody used in the disclosed assay and method specifically binds to IL-33.Terms such as "specifically bind" mean that the antibody or its antigen-binding fragment forms a complex with the antigen that is relatively stable under physiological conditions.Methods for determining whether an antibody specifically binds to an antigen are well known in the art, and include, for example, equilibrium dialysis, surface plasmon resonance, etc. For example, as used herein, an antibody that "specifically binds" to IL-33 includes an antibody that has a K of less than about 1000 nM, less than about 500 nM, less than about 300 nM, less than about 200 nM, less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, or less than about 0.5 nM, as measured by surface plasmon resonance assay. D However, an isolated antibody that specifically binds human IL-33 may have cross-reactivity to other antigens, such as IL-33 molecules from other (non-human) species.

[0049] In some embodiments, the IL-33 antagonist is an anti-IL-33 antibody, or an antigen-binding fragment thereof, that comprises a heavy chain variable region (HCVR), a light chain variable region (LCVR), and / or a complementarity determining region (CDR) that comprises any of the amino acid sequences of the anti-IL-33 antibodies described in U.S. Patent Nos. 10,000,564 and 9,453,072. In certain embodiments, the IL-33 antagonist is an anti-IL-33 antibody that has the binding characteristics of the reference antibodies described in U.S. Patent Nos. 10,000,564 and 9,453,072.

[0050] Other anti-IL-33 antibodies and antigen-binding fragments thereof that may be used in the methods described herein are disclosed in EP1725261 and U.S. Pat. Nos. 9,970,944, 8,187,596, WO2011031600, WO2015099175 and U.S. Pat. No. 9,758,578, WO2015106080 and U.S. Pat. No. 10,059,764 (ANB020), 2016 / 0168242, WO2016 / 077381 and U.S. Pat. No. 10,093,730, WO2016 / 077366 and U.S. Pat. No. 2018 / 0171405, or WO2016 / 156440 and U.S. Pat. No. 2018 / 0207265, each of which is incorporated herein by reference in its entirety.

[0051] b.IL-33 trap In some embodiments, the IL-33 antagonist or inhibitor that can be used in the disclosed methods and assays is a receptor-based IL-33 trap. An exemplary IL-33 trap comprises at least one IL-33 binding domain that contains the IL-33 binding portion of an IL-33 receptor protein, such as ST2. In certain embodiments, the IL-33 trap further comprises an IL-33 co-receptor, such as an IL-1 receptor accessory protein, or the extracellular portion of IL-1RAcP. The IL-33 trap may also comprise at least one multimerization component that functions to bind the various components of the trap together.

[0052] In one embodiment, the IL-33 trap described herein for use in the disclosed methods and assays is disclosed in U.S. Pat. No. 9,637,535 and WO2014 / 152195, each of which is incorporated by reference in its entirety.

[0053] Generally, the IL-33 trap comprises a first IL-33 binding domain (D1) bound to a multimerization domain (M). In certain embodiments, the IL-33 antagonist comprises a second IL-33 binding domain (D2) bound to D1 and / or M. According to certain embodiments, D1 comprises an IL-33 binding portion of the ST2 protein. The IL-33 binding portion of the ST2 protein may comprise or consist of all or a portion of the extracellular domain of the ST2 protein. In certain embodiments, the ST2 protein is a human ST2 protein. As used herein, "human ST2 protein" refers to the ST2 protein set forth in amino acids 1-556 of Accession No. NP_057316.3, incorporated by reference in its entirety. According to certain embodiments, D2 comprises the extracellular portion of the IL-1RAcP protein.

[0054] The individual components of the IL-33 Trap can be arranged relative to one another in a variety of ways that result in a functional antagonist molecule capable of binding to IL-33. For example, D1 and / or D2 may be attached to the N-terminus of M. In other embodiments, D1 and / or D2 are attached to the C-terminus of M. In yet other embodiments, D1 is attached to the N-terminus of D2 and D2 is attached to the N-terminus of M, resulting in an in-line fusion from the N-terminus to the C-terminus of the antagonist molecule represented by the formula D1-D2-M.

[0055] In certain embodiments, the IL-33 antagonist has two multimerization domains, M1 and M2, which are identical to each other. For example, M1 can be an Fc domain with a specific amino acid sequence, and M2 is an Fc domain with the same amino acid sequence as M1.

[0056] c. Other IL-33 antagonists Other agents that may act as IL-33 antagonists and may be used in the disclosed methods and assays include immunoadhesins, peptibodies, soluble ST2 or derivatives thereof, anti-IL-33 receptor antibodies (e.g., anti-ST2 antibodies, such as AMG-282 (Amgen) or STLM15 (Janssen), or any of the anti-ST2 antibodies described in WO2012 / 113813 and U.S. Pat. No. 9,309,319, WO2013 / 173761 and U.S. Pat. No. 9,982,054, WO2013 / 165894 and U.S. Pat. Nos. 9,951,137, 8,444,987, or 7,452,980, each of which is incorporated by reference in its entirety). Other IL-33 antagonists for use in the disclosed methods and assays include ST2-Fc proteins, such as those described in WO2013 / 173761 and U.S. Patent No. 9,982,054, or WO2013 / 165894 and U.S. Patent No. 9,951,137, each of which is incorporated by reference in its entirety.

[0057] 6. Capture Reagents In one embodiment, the capture reagent used in the disclosed method and assay is an IL-33 antagonist as described above, for example, an antibody, preferably an anti-IL-33 antibody, preferably an anti-human IL-33 antibody. An exemplary anti-IL-33 antibody is disclosed in U.S. Patent No. 10,000,564, the entirety of which is incorporated by reference. Other anti-IL-33 antibodies that can be used are described above. In one embodiment, the capture reagent is biotinylated.

[0058] In some embodiments, the capture reagent is immobilized or bound to a solid support, which can be a microplate, for example a streptavidin-coated microplate.

[0059] In some embodiments, the capture reagent is an IL-33 antagonist as described above.

[0060] C. Companion Diagnostics In one embodiment, the disclosed methods and assays for detecting and quantifying IL-33 are used as companion diagnostic methods in combination with a treatment designed to reduce circulating levels of IL-33 in a treated subject or to increase circulating levels of IL-33 in a treated subject. The treatment may include administration of an IL-33 antagonist or administration of IL-33. Exemplary IL-33 antagonists are described above and include, but are not limited to, anti-IL-33 antibodies, anti-IL-33 fusion proteins, sST decoy receptors, or combinations thereof.

[0061] One embodiment provides a method for monitoring treatment of an IL-33-related disorder in a subject undergoing a treatment comprising administration of an IL-33 antagonist or administration of IL-33 as described above. Exemplary diseases, disorders, or conditions treated with IL-33 inhibitors or IL-33 include, but are not limited to, asthma, eosinophilic or non-eosinophilic asthma, atopic dermatitis, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, Crohn's disease, colitis, ulcerative colitis, multiple sclerosis, arthritis, allergic rhinitis, atopic dermatitis, eosinophilic esophagitis, psoriasis, nasal polyps, Alzheimer's disease, atherosclerosis, myocardial infarction, ischemic stroke, and fibrotic conditions, including but not limited to Dupuytren's disease, periarthritis of the shoulder, periarticular fibrosis, keloid or hypertrophic scars, endometriosis, abdominal adhesions, perineural fibrosis, Ledderhose's disease, Peyronie's disease, peritendinous adhesions, and periarticular fibrosis.

[0062] The methods and assays described herein can be used to assess, detect, or quantify circulating IL-33 levels in a subject before and after treatment of the subject with one or more pharmaceutical compositions containing the above-mentioned IL-33 antagonists (e.g., pharmaceuticals particularly related to a mechanism of action involving IL-33), with anti-inflammatory therapy, or with immunoabsorption therapy (or IL-33 is assessed after such treatment and the concentration or amount of IL-33 is compared to a predetermined level or to the level measured in the subject before treatment). An unfavorable concentration or amount of IL-33 observed after treatment confirms that the subject will not benefit from receiving further or continued treatment, whereas a favorable concentration or amount of IL-33 observed after treatment confirms that the subject will benefit from receiving further or continued treatment.

[0063] In one embodiment, an unfavorable concentration of IL-33 detected by the disclosed methods and assays in a sample from a subject undergoing a treatment incorporating an IL-33 inhibitor is a level of IL-33 that is the same as or higher than the level measured in the subject prior to treatment. In one embodiment, a favorable concentration of IL-33 detected by the disclosed methods and assays in a sample from a subject undergoing a treatment incorporating an IL-33 inhibitor is a level of IL-33 that is lower than the level of IL-33 measured in a sample from the subject prior to treatment.

[0064] In another embodiment, an unfavorable concentration of IL-33 detected using the disclosed methods and assays in a sample from a subject undergoing a treatment incorporating IL-33 is a lower level than the level of IL-33 measured in a sample from the subject prior to treatment. In another embodiment, a favorable concentration of IL-33 detected using the disclosed methods and assays in a sample from a subject undergoing a treatment incorporating IL-33 is a higher level of IL-33 than the level of IL-33 measured in a sample from the subject prior to treatment.

[0065] Ascertainment of circulating IL-33 levels will facilitate the management of clinical trials and the provision of improved patient care.

[0066] III. Kit Also provided is a kit for assaying a test sample for the presence, amount or concentration of IL-33 (or a fragment thereof) in the test sample, the kit including at least one component for assaying the test sample for IL-33 (or a fragment thereof) and instructions for assaying the test sample for IL-33 (or a fragment thereof).

[0067] In one embodiment, the kit comprises a detection reagent as described above, a capture reagent as described above, a solid support, other reagents, and written instructions for carrying out the assay. The detection and capture reagents can be the same or different IL-33 antagonists as described above, such as a monoclonal antibody (or a fragment, variant, or fragment of a variant thereof), a fusion protein, an IL-33 trap, or an apatamer, optionally immobilized on a solid phase.

[0068] The detection reagent is generally labeled with a detectable label, such as a chemiluminescent label. The detection reagent can incorporate a detectable label as described herein, such as a fluorophore, a radioactive moiety, an enzyme, a biotin / avidin label, a chromophore, a chemiluminescent label, or the kit can include a reagent for performing detectable labeling. The antibody, calibrator, and / or control can be provided in separate containers or can be pre-dispensed in a suitable assay format, such as a microtiter plate. In one embodiment, the IL-33 detection reagent is labeled with ruthenium.

[0069] In some embodiments, the kit contains a biotin-labeled capture reagent and a streptavidin-coated solid support, such as a microtiter plate or an electrochemiluminescence platform. In some embodiments, the capture reagent and the microtiter plate or the electrochemiluminescence platform are provided in separate containers. In other embodiments, the kit contains a capture reagent-coated microtiter or electrochemiluminescence platform plate. The kit also contains the above-mentioned acidic and buffer solutions for treating the sample.

[0070] The kit may include a calibrator or control, such as isolated or purified IL-33. The kit may include at least one container (e.g., tube, microtiter plate or strip or electrochemiluminescence platform) for performing the assay, and / or a buffer such as an assay buffer or a wash buffer, any one of which may be provided as a concentration solution, a substrate solution for a detectable label (e.g., enzyme label), or a stop solution. Preferably, the kit includes all the components necessary to perform the assay, i.e., reagents, standards, buffers, diluents, etc. The instructions may be in paper form or computer readable form.

[0071] Optionally, the kit includes quality control components (e.g., sensitivity panels, calibrators, and positive controls). Preparation of quality control reagents is well known in the art and is described in the insert sheets of various immunodiagnostic products. Sensitivity panel members are optionally used to establish assay performance characteristics and are also optionally useful indicators of the integrity of the immunoassay kit reagents and standardization of the assay.

[0072] The kit may also optionally include other reagents required for performing diagnostic assays or facilitating quality control evaluation, such as buffers, salts, enzymes, enzyme cofactors, enzyme substrates, detection reagents, etc. Other components, such as buffers and buffer solutions for isolating and / or processing test samples (e.g., pretreatment reagents), may also be included in the kit. The kit may further include one or more other controls. One or more of the components of the kit may be lyophilized. In this case, the kit may further include a reagent suitable for reconstituting the lyophilized components.

[0073] The various components of the kit are optionally provided in suitable containers, such as microtiter plates, as needed. The kit may further include a container for holding or storing a sample (e.g., a container or cartridge for a urine sample). If appropriate, the kit may also optionally contain reaction vessels, mixing vessels, and other components that facilitate the preparation of reagents or test samples. The kit may also include one or more instruments to assist in obtaining a test sample, such as a syringe, pipette, forceps, measuring spoon, etc. EXAMPLES

[0074] Example I: Assay Format FIG. 1 is a diagram of an exemplary assay for detecting IL-33. This method for quantifying IL-33 is a sandwich immunoassay on an electrochemiluminescence platform. The procedure uses streptavidin-coated microplates and uses biotinylated anti-IL-33 antibodies as capture reagents. The method includes acid pretreatment of serum samples to dissociate soluble ligand:binding partner complexes present in the sample and improve detection of IL-33 in the presence of binding partners, such as anti-IL-33 therapeutics and / or soluble ST2, thus providing a quantitative measurement of the level of total IL-33. The acidified samples were then neutralized in a basic solution containing a labeled anti-IL-33 detection antibody that, in one embodiment, can compete with soluble ST2 receptors and drugs for binding to IL-33.

[0075] Exemplary acids that can be used include, but are not limited to, acetic acid, sulfuric acid, and hydrochloric acid. The sample can be neutralized using a buffered basic solution, such as a Tris solution.

[0076] Exemplary IL-33 antibodies that can be used are described in U.S. Patent No. 10,000,564, which is incorporated by reference in its entirety. Other anti-IL-33 antibodies that can be used in the disclosed methods include, but are not limited to, those described in U.S. Patent No. 9,758,578 and U.S. Patent Application Publication No. 2018 / 0037644.

[0077] In one embodiment, the standard, control and sample are diluted with acetic acid and neutralized using a Tris base solution containing a detection reagent, for example, a ruthenium-labeled anti-human IL-33 antibody.Anti-IL-33 antibody and anti-ST2 antibody are also added to the Tris solution to minimize interference from drugs or endogenous binding partners.The neutralized standard, control and sample are then added to the plate.The IL-33 captured on the plate is measured in a plate reader by the chemiluminescence signal generated by the ruthenium label when a voltage is applied to the plate.The resulting electrochemiluminescence signal (i.e., count) is proportional to the amount of IL-33 present in the serum sample.

[0078] Example II: Minimization of endogenous binding partner interference material and method Recombinant human ST2 permissibility was tested using four different conditions of the assay (described below), and the first (capture) step in all conditions was the addition of a biotinylated anti-IL-33 monoclonal antibody to a streptavidin plate.

[0079] For the stepwise assay (capture-analyte-detection, CAD), the sample (containing the analyte, IL-33) was first diluted in an acidic solution and allowed to incubate. The plate was then washed and the acidified sample was further diluted in a basic neutralization buffer before being added to the assay plate. After sample incubation, the assay plate was washed and a labeled detection monoclonal antibody solution was added. After detection reagent incubation, the plate was washed, buffer was added and the plate was read. This assay was also performed without an acidification step, in which the sample was diluted in assay buffer before being added to the assay plate.

[0080] For assays where analyte and detector are added simultaneously (C-AD), samples were first diluted in an acidic solution and allowed to incubate. The plate was washed and then the acidified samples were further diluted with a basic neutralization buffer containing a labeled detection monoclonal antibody before being added to the assay plate. After sample incubation, the plate was washed, buffer was added and the plate was read. This assay was also performed without an acidification step, where samples were first diluted in assay buffer, followed by a next dilution in assay buffer containing a labeled detection monoclonal antibody before adding the samples to the assay plate.

[0081] Recombinant IL-33 at 36 pg / mL was tested in the presence of increasing concentrations of recombinant soluble ST2 under four different conditions of the assay, as described above, as shown in FIG. 2A.

[0082] result Acid treatment is necessary to detect recombinant human IL-33 in the presence of recombinant ST2. Adding an acid treatment step to the CAD assay improves ST2 tolerance to approximately 12 ng / mL, and using the C-AD assay format with acid treatment can further improve ST2 tolerance to over 50 ng / mL (Figure 2A). Acid treatment is also necessary to improve the detection of endogenous IL-33 in human serum. Detection of endogenous IL-33 is improved using the C-AD assay format due to reduced assay interference from endogenous binding partners compared to the CAD assay format (Figure 2B).

[0083] Example III: Precision and Specificity: Endogenous IL-33 material and method Assay specificity for IL-33 was confirmed by analyzing two different individual serum samples in the C-AD assay with acid treatment described in Example II, tested both with and without the addition of excess recombinant human ST2 or 200 μg / mL anti-IL-33 antibody in a basic neutralizing solution containing detection reagent.

[0084] Two individuals were tested using the C-AD assay with acid treatment as described in Example II. Data represent four separate replicate measurements performed on five separate days.

[0085] result This assay is specific for endogenous IL-33, as the addition of a binding partner, e.g., recombinant ST2, or an anti-IL-33 monoclonal antibody to the neutralizing solution inhibits the detection of IL-33. Figure 3 is a bar graph showing endogenous IL-33 specificity.

[0086] The assay shows acceptable precision with coefficients of variation (%CV) of 7.1 and 12.3 for individuals 1 and 3, respectively. Figure 4 is a graph showing the precision of the assay in quantifying endogenous IL-33 in human serum.

[0087] Example IV: Detection of IL-33 in the presence of anti-IL-33 monoclonal antibodies (anti-IL-33 monoclonal antibody tolerance) material and method Figure 5 is a line graph showing the acceptability of the method to detect IL-33 in the presence of anti-IL-33 monoclonal antibodies. Recombinant IL-33 at 90 pg / mL was tested in the C-AD method with acid treatment described in Example II in the presence of increasing concentrations of anti-IL-33 monoclonal antibodies as shown in Figure 5. The assay was modified by adding excess anti-drug monoclonal antibodies and anti-ST2 monoclonal antibodies to the neutralization solution.

[0088] result The acid treatment is important to detect human IL-33 in the presence of anti-IL-33 monoclonal antibodies. The addition of the detection reagent to the neutralization solution, together with the addition of anti-drug monoclonal antibodies and anti-ST2 monoclonal antibodies, improves the anti-IL-33 monoclonal antibody tolerance in the assay to >500 μg / mL.

[0089] Example V: Endogenous IL-33 levels in normal and diseased individuals material and method Twenty-five individuals from each of the four different populations were purchased from a commercial vendor and screened for endogenous IL-33 using the C-AD assay with acid treatment as described in Example II.

[0090] result 6 is a graph of endogenous IL-33 (pg / mL) in serum from normal individuals and individuals with asthma, COPD, and atopic dermatitis. All test individuals produced IL-33 concentrations below 31 pg / mL.

[0091] Example VI: Humanized Mouse Data material and method Humanized IL-33 mice were treated with house dust mites (HDM) for 15 weeks as a model of human respiratory disease. Exemplary humanized IL-33 mice are disclosed in US Patent Publication No. 20170311580, which is incorporated by reference in its entirety. Samples were tested in a modified version of the C-AD assay using acid treatment as described in Example IV.

[0092] result Figures 7A and 7B show human IL-33 (pg / mL) from treated and control mice. Saline controls, HDM-treated controls, and isotype controls showed similar levels of human IL-33 at the end of treatment. Mice administered anti-IL-33 monoclonal antibodies showed a significant increase in serum IL-33 levels.

[0093] A total human IL-33 assay has been developed with a sensitivity of 12.5 pg / mL in pure serum. Collectively, the data indicate that the acid treatment step is critical to remove IL-33 endogenous binding partners. Recombinant / endogenous ST2 tolerance is improved by adding a detection antibody to the neutralization solution. The assay shows specificity for endogenous human IL-33. HDM-treated mice administered anti-IL-33 antibody showed an increase in human IL-33 due to the binding target assuming the half-life of the drug, while HDM and isotype controls appeared to remain at baseline.

[0094] In the foregoing specification, the invention has been described in relation to specific embodiments thereof, and numerous details have been set forth for purposes of illustration, but it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments, and that some of the details described herein may be varied considerably without departing from the underlying principles of the invention.

[0095] All references cited herein are incorporated by reference in their entirety. The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics, and therefore, reference should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.

Claims

1. 1. A method for reducing IL-33 assay interference, comprising: acidifying the sample to a pH sufficient to dissociate IL-33 from IL-33 complexes in said sample; followed by neutralizing the acidified sample with a buffered basic solution comprising a detection reagent and a blocking agent that inhibits IL-33 complex formation, wherein the detection reagent and the blocking agent do not compete for binding to IL-33; adding a capture reagent to the sample; detecting the detection reagent; wherein the amount of the detection reagent detected correlates with the amount of the IL-33 in the sample.

2. 10. The method of claim 1, wherein the sample comprises blood, serum, or plasma.

3. The method of claim 2, wherein the sample is derived from a subject administered an IL-33 formulation.

4. The method of claim 3, wherein the IL-33 preparation comprises an anti-IL-33 antibody.

5. The method of any one of claims 1 to 4, wherein the IL-33 complex comprises IL-33 non-covalently bound to a protein.

6. The method of claim 5 , wherein the protein is an endogenous serum protein.

7. The method of claim 5, wherein the protein is ST2 or an IL-33 binding fragment thereof.

8. The method of claim 5, wherein the protein is an anti-IL-33 antibody or an IL-33 binding fragment thereof.

9. The method of any one of claims 1 to 8, wherein the sample is acidified to a pH of from 3 to 5.

10. The method of any one of claims 1 to 9, wherein the sample is acidified for 5 to 60 minutes.

11. The method of any one of claims 1 to 10, wherein the detection reagent comprises an anti-IL-33 antibody conjugated to a detectable label.

12. 12. The method of any one of claims 1 to 11, wherein the detection reagent comprises a detectable agent selected from the group consisting of rare transition metal particles, fluorophores, chromophores, quantum dots, and precious metal nanoparticles.

13. The method of any one of claims 1 to 12, wherein the detection reagent is labelled with ruthenium.

14. The method of any one of claims 1 to 13, wherein the capture reagent is conjugated to a solid support.

15. The method of any one of claims 1 to 14, wherein the capture reagent is biotinylated.

16. The method of any one of claims 1 to 15, wherein the sample is acidified with acetic acid.

17. The method of any one of claims 1 to 16, wherein the buffered basic solution comprises a blocking agent, the blocking agent being an antibody.

18. The method of any one of claims 1 to 17, wherein the buffered basic solution comprises a blocking agent, and the blocking agent is an anti-ST2 antibody.

19. The method of any one of claims 1 to 18, wherein the capture reagent is added to the sample during the acidification step.

20. The method of any one of claims 1 to 19, wherein the blocking agent is added to the sample after the neutralization step.

21. The method of any one of claims 1 to 20, wherein the capture reagent and the blocking agent are added to the sample after the neutralization step.

22. The method according to any one of claims 1 to 21, wherein the IL-33 has a sensitivity of 12.5 pg / mL.

23. The method of any one of claims 1 to 22, wherein the IL-33 has an ST2 tolerance of more than 50 ng / mL.

24. The method of any one of claims 1 to 23, wherein the sample is obtained from a subject diagnosed with or suspected of having an inflammatory disease or disorder.

25. The method of any one of claims 1 to 24, wherein the sample is obtained from a subject diagnosed with or suspected of having asthma, chronic obstructive pulmonary disease, or atopic dermatitis.

26. The method of claim 14 , wherein the solid support is an electrochemiluminescence platform.

27. The method according to any one of claims 1 to 26, wherein the amount of IL-33 is determined by correlating the amount of detection reagent detected with a predetermined reference standard.

28. 1. A method for quantifying interleukin-33 in a serum sample, comprising: acidifying the serum sample to a pH sufficient to dissociate IL-33 complexes in the sample; neutralizing the acidified sample with a buffered basic solution comprising (a) an anti-human IL-33 antibody labeled with a detectable label, and (b) an anti-human ST2 antibody, wherein the anti-human IL-33 antibody and the anti-human ST2 antibody do not compete for binding to IL-33; adding the sample to an avidin-coated solid support containing a biotinylated anti-human IL-33 antibody; detecting the detectable label on the avidin-coated solid support; wherein the amount of detectable label detected correlates with the amount of IL-33 in the sample.

29. 29. The method of claim 28, wherein the solid support is a streptavidin-coated electrochemiluminescence platform.

30. 30. The method of any one of claims 28 or 29, wherein the detectable label is ruthenium.

31. The method of any one of claims 28 to 30, wherein the anti-human ST2 antibody is present in an amount sufficient to reduce binding of ST2 to IL-33 in the sample.

32. The method of any one of claims 28 to 30, wherein the IL-33 has a sensitivity of 12.5 pg / mL and an ST2 tolerance of greater than 50 ng / mL.

Citation Information

Patent Citations

  • Method for determining the concentration of an analyte

    JP2010503854A